JPMorgan Chase & Co’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-5,096
| Closed | -$671K | – | 5548 |
|
|
2020
Q4 | $671K | Buy |
5,096
+1,019
| +25% | +$134K | ﹤0.01% | 3598 |
|
|
2020
Q3 | $204K | Buy |
4,077
+202
| +5% | +$10.1K | ﹤0.01% | 3726 |
|
|
2020
Q2 | $185K | Sell |
3,875
-12,517
| -76% | -$598K | ﹤0.01% | 3704 |
|
|
2020
Q1 | $803K | Buy |
16,392
+11,435
| +231% | +$560K | ﹤0.01% | 3067 |
|
|
2019
Q4 | $284K | Buy |
4,957
+286
| +6% | +$16.4K | ﹤0.01% | 3696 |
|
|
2019
Q3 | $168K | Buy |
4,671
+1,631
| +54% | +$58.7K | ﹤0.01% | 3816 |
|
|
2019
Q2 | $86K | Sell |
3,040
-907
| -23% | -$25.7K | ﹤0.01% | 4072 |
|
|
2019
Q1 | $93K | Buy |
3,947
+2,093
| +113% | +$49.3K | ﹤0.01% | 4025 |
|
|
2018
Q4 | $26K | Sell |
1,854
-14,858
| -89% | -$208K | ﹤0.01% | 4454 |
|
|
2018
Q3 | $167K | Buy |
+16,712
| New | +$167K | ﹤0.01% | 3930 |
|